Category: Medical Stocks

News $MJNA – #MedicalMarijuana Inc. Featured by Reuters: Mexico Government Grants Import of RSHO-X, Market Estimated $1-2 Billion for CBD Hemp Oil Over 10 Years

SAN DIEGO, Feb. 04, 2016 (GLOBE NEWSWIRE) — Medical Marijuana, Inc.’s (OTC Pink:MJNA) is proud to inform shareholders and the public that Reuters wire news agency featured the Company in the article California-based Medical Marijuana Eyes Mexico as Next Big Market.  In an historic move, the government of Mexico issued two of the country’s first permits to import a cannabidiol product, RSHO-X, from the U.S. headquartered industrial hemp company. “With Mexico’s government’s decision to approve import permits, we are extremely proud of our capability to provide our cannabidiol (CBD) hemp oil, RSHO-X, to the more than 120 million residents of

Globe Newswire

Stereotaxis Announces Warrants Offering

ST. LOUIS, Sept. 4, 2015 (GLOBE NEWSWIRE) — Stereotaxis, Inc. (NASDAQ:STXS), a global leader in innovative technologies for the treatment of cardiac arrhythmias, announced today that it will conduct a registered offering of subscription warrants to the holders of its common shares, which will function similarly to a rights offering. The Company has declared the record date for determination of stockholders eligible to participate as September 9, 2015 at 5:00 p.m. Eastern Time. At such time, each holder will be issued, at no charge, one subscription warrant for every four common shares held, which will entitle the holder to purchase

Globe Newswire

Sientra(R) Files S-1 Registration Statement for Proposed Follow-On Public Offering

SANTA BARBARA, Calif., Sept. 3, 2015 (GLOBE NEWSWIRE) — Sientra, Inc. (NASDAQ: SIEN), a medical aesthetics company, today filed a registration statement on Form S-1 with the U.S. Securities and Exchange Commission for a proposed underwritten follow-on public offering of approximately $75 million of shares of its common stock to be sold by the company. Sientra intends to grant the underwriters a 30-day option to purchase additional shares of its common stock. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to


MacroGenics to Participate in Two Upcoming Investor Conferences

ROCKVILLE, Md., Sept. 03, 2015 (GLOBE NEWSWIRE) — MacroGenics, Inc. (Nasdaq: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, as well as autoimmune disorders and infectious diseases, today announced that its senior management will participate in two upcoming investor conferences. These two conferences include: The Citi 10th Annual Biotech Conference, which will be held on Thursday, September 10, 2015 at the Mandarin Oriental Hotel in New York; and The 2015 Morgan Stanley Healthcare Conference, which will be held on Friday, September 18, 2015 at the Grand Hyatt New York.

Client News

Epiq Systems Adopts Equity Inducement Plan to Attract Future Employees

KANSAS CITY, Kan., Sept. 3, 2015 (GLOBE NEWSWIRE) — Epiq Systems, Inc. (NASDAQ:EPIQ) (“Epiq”), a leading global provider of integrated technology solutions for the legal profession, today announced that its Board of Directors has adopted the 2015 Inducement Plan (the “Plan”) in accordance with NASDAQ Listing Rule 5635(c)(4). The Plan reserves 200,000 shares of common stock, subject to adjustment, for the grant of inducement equity awards to individuals not previously employees or non-employee directors of Epiq. The Plan will enable Epiq to issue awards to talented individuals as an inducement to join Epiq, enabling Epiq to attract the best available

Globe Newswire

The Cooper Companies Announces Third Quarter 2015 Results

PLEASANTON, Calif., Sept. 3, 2015 (GLOBE NEWSWIRE) — The Cooper Companies, Inc. (NYSE:COO) today announced financial results for the fiscal third quarter ended July 31, 2015. Revenue increased 7% year-over-year to $461.7 million. CooperVision (CVI) revenue up 10% to $385.5 million. CooperSurgical (CSI) revenue down 8% to $76.2 million. GAAP earnings per share (EPS) $0.91, down 89 cents or 49% from last year’s third quarter. Non-GAAP EPS $1.97, down 3 cents or 2% from last year’s third quarter. See “Reconciliation of GAAP to Non-GAAP Results” below. Commenting on the results, Robert S. Weiss, Cooper’s president and chief executive officer said,

Spectranetics Names Stacy McMahan Chief Financial Officer

COLORADO SPRINGS, Colo., Aug. 27, 2015 (GLOBE NEWSWIRE) — The Spectranetics Corporation (NASDAQ:SPNC) today announced that Stacy McMahan has been named Chief Financial Officer, effective September 28, 2015. In this role, Ms. McMahan will report directly to Scott Drake, President and Chief Executive Officer. Ms. McMahan has more than 25 years of finance leadership experience, including Chief Financial Officer and Vice President of Finance with responsibility for global, treasury, tax, internal audit, and decision support groups of high-profile public companies. Ms. McMahan currently serves as Senior Vice President, Chief Financial Officer and Treasurer of MSA Safety Incorporated (NYSE:MSA). Prior to

Portola Pharmaceuticals to Present Preclinical Data with Andexanet Alfa and Factor Xa Inhibitor Edoxaban at European Society of Cardiology Congress 2015

SOUTH SAN FRANCISCO, Aug. 27, 2015 (GLOBE NEWSWIRE) — Portola Pharmaceuticals (Nasdaq: PTLA) today announced that results of a preclinical study of andexanet alfa will be presented in a moderated poster session at the European Society of Cardiology (ESC) 2015 Congress in London, U.K. The study assessed the activity of andexanet alfa in reversing anticoagulation and reducing bleeding in a validated animal model using Daiichi Sankyo’s oral, once-daily, direct Factor Xa inhibitor edoxaban as the anticoagulant. Andexanet alfa, a U.S. Food and Drug Administration (FDA)-designated breakthrough therapy, is a recombinant protein specifically designed to reverse the anticoagulant activity of Factor

Sientra(R) Launches First-in-Kind 5th Generation Round Breast Implant

Innovative Style 107 round implant incorporates high-strength cohesive gel (HSC+) previously available only in Sientra’s shaped implants   Provides novel solution to address certain challenges in breast surgery   Company also initiates The Orange Dot™ exclusive consumer on-line awareness and education campaign on RealSelf SANTA BARBARA, Calif., Aug. 27, 2015 (GLOBE NEWSWIRE) — Sientra, Inc. (NASDAQ:SIEN), a medical aesthetics company, today announced the launch of its newest implant, the Style 107 — an innovative smooth round breast implant integrating High-Strength Cohesive HSC+ gel, the Company’s most cohesive silicone gel, which until now was only available in its anatomically shaped implants.


QLT and InSite Vision Agree on Amended and Restated Merger Agreement

VANCOUVER, British Columbia, Aug. 27, 2015 (GLOBE NEWSWIRE) — QLT Inc. (NASDAQ:QLTI) (TSX:QLT) (“QLT”) today announced that it has entered into an Amended and Restated Merger Agreement with InSite Vision Incorporated (OTCBB:INSV) (“InSite Vision”), pursuant to which QLT will acquire InSite Vision in a share-for-share transaction. The revised merger consideration will be payable in QLT common shares based on an exchange ratio equal to 0.078x of a QLT common share per share of InSite common stock, subject to two adjustment mechanisms. First, the merger consideration will include a “collar” mechanism, which provides that the exchange ratio will be adjusted so

Photo Release — Hemispherx Biopharma Posts Photographs of the Ampligen Facility in New Brunswick, New Jersey

NEW BRUNSWICK, N.J., Aug. 27, 2015 (GLOBE NEWSWIRE) — Hemispherx Biopharma (NYSE MKT:HEB) recently hosted a Stockholder Open House in their manufacturing facility in New Brunswick, NJ. During the tour, visitors were taken throughout the Alferon® and Ampligen® manufacturing suites and also via our Research and Development labs, where there has been a significant amount of resources spent on trying to find a biomarker for Ampligen® to treat Chronic Fatigue Syndrome (CFS). A photograph of the Research and Development facility is available for viewing on our website at A photo accompanying this release is available at Thomas Equels,

Notch3 Biomarker Results and Updated Data From OncoMed’s Phase 1b/2 PINNACLE Clinical Trial Accepted for Presentation at the 16th World Conference on Lung Cancer

REDWOOD CITY, Calif., Aug. 27, 2015 (GLOBE NEWSWIRE) — New biomarker data related to OncoMed Pharmaceuticals Inc. (NASDAQ:OMED) Phase 1b/2 PINNACLE clinical trial of tarextumab (Anti-Notch 2/3, OMP-59R5) in small cell lung cancer (SCLC) will be presented by academic collaborator, Anne Chiang M.D., Ph.D., of the Yale School of Medicine, during a mini oral discussion session at the upcoming 16th World Conference on Lung Cancer taking place September 6-9 in Denver, CO. Details for the presentation are provided below. Wednesday, September 9, 2015 Mini27.08: NOTCH3 Protein Expression and Outcome in Small Cell Lung Cancer (SCLC) and Therapeutic Targeting with Tarextumab (Anti-Notch


Westmead Hospital Research Provides Significant Data Supporting the Ablation Effectiveness of Stereotaxis Magnetic Navigation

ST. LOUIS, Aug. 27, 2015 (GLOBE NEWSWIRE) — Stereotaxis, Inc. (NASDAQ:STXS) and Westmead Hospital in Australia today announced findings of a recent study comparing the stability of a Niobe® remote magnetic navigation system catheter group and a manually controlled catheter group in a validated cardiac wall motion simulator. “The Niobe system has long demonstrated an enhanced safety profile in comparison to conventional ablations, but its efficacy with lesion creation in highly mobile cardiac regions has not been adequately studied,” said Pramesh Kovoor, M.D., Ph.D., Director of Cardiac Services at Westmead Hospital and Associate Professor at the University of Sydney. “We

AGTC Announces Achievement of XLRS Patient Enrollment Milestone in Biogen Collaboration

GAINESVILLE, Fla., Aug. 27, 2015 (GLOBE NEWSWIRE) — Applied Genetic Technologies Corporation (Nasdaq:AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare eye diseases, today announced it had met a patient enrollment milestone in the X-Linked Retinoschisis (XLRS) clinical study, which will earn AGTC a $5 million payment from Biogen. AGTC filed an Investigational New Drug (IND) application with the U.S. Food and Drug Administration (FDA) in March to conduct a Phase I/II clinical trial of the company’s gene therapy product candidate for the treatment of XLRS. Utilizing technology licensed from


Amarantus Moves Annual Meeting Date Forward to September 2, 2015

SAN FRANCISCO and GENEVA, Aug. 26, 2015 (GLOBE NEWSWIRE) — Amarantus BioScience Holdings, Inc. (OTCQX:AMBS), a biotechnology company developing therapeutic and diagnostic product candidates in orphan indications and neurology, announced that its 2015 Annual Meeting of Stockholders, that was previously adjourned to September 4, 2015 due to the lack of requisite quorum, has now been moved to September 2, 2015. The adjourned annual meeting will now take place on September 2, 2015 at 10:00 a.m. EDT at Sichenzia Ross Friedman Ference LLP, 61 Broadway, 32nd Floor, New York, New York 10006. The Company encourages all stockholders who have not yet

Client News

Stealth Mark Releases iOS Mobile Application for iPhone

SCHAUMBURG, Ill., Aug. 26, 2015 (GLOBE NEWSWIRE) — Wellness Center USA, Inc.  (OTCQB:WCUI), today announced that its wholly-owned subsidiary, StealthCo, Inc. (dba: Stealth Mark), has released its iOS mobile phone application, “StealthFire Mobile.” The application enables customers to use their iPhones to quickly and easily scan the Stealth Mark® microparticle security label and verify the customized information which describes the product or item on which the Stealth Mark® label is attached. Utilizing a powerful scan engine, the application not only provides the user with information regarding an item, but also lists location information, in both standard address and GPS formats.


Surgical Care Affiliates, Inc. Announces Appointment of New Director

DEERFIELD, Ill., Aug. 25, 2015 (GLOBE NEWSWIRE) — Surgical Care Affiliates, Inc. (NASDAQ:SCAI) (“SCA”) announced today that Michael A. Sachs will join its Board of Directors, effective September 1, 2015. Mr. Sachs served as Chairman and CEO of Sg2, a healthcare analytics and consulting firm which was sold to MedAssets last year. Prior to founding Sg2, Mr. Sachs served as Chairman and CEO of Sachs Group, which provided health care planning and marketing services to hospitals and health plans, and founded bSwift, an on-line benefits administration firm that was acquired by Aetna. Previously, Mr. Sachs was a consultant with Ernst


Cookeville Medical Center Selects Allscripts for Chronic Care Management (CCM) Program

CHICAGO, Aug. 25, 2015 (GLOBE NEWSWIRE) — Cookeville Medical Center in Cookeville, Tenn., selected Allscripts (Nasdaq:MDRX) Chronic Care Management (CCM) Program to more easily manage and improve care for patients with chronic conditions while increasing Centers for Medicare & Medicaid Services (CMS) reimbursements. Cookeville Medical Center is an existing Allscripts Professional EHR™ client that selected the CCM program to improve engagement with patients for better management of chronic diseases. The CCM program enables Cookeville to offer patient-centered care plans with limited impact to existing operations. The Allscripts CCM program features services from Allscripts’ Professional Physicians business unit to assist care